iconstar paper   Hepatitis C Articles (HCV)  
Back grey arrow rt.gif
 
 
HCV Treatment / Vulnerable Populations
 
 
  State of the Hepatitis C Virus Care Cascade, USA, Gobally - (01/11/21)
 
An Integrated Community-Based Approach to Manage and Eliminate Hepatitis C in Vulnerable Populations: The Ontario Hepatitis C Teams Experience - (11/13/20)
 
POINT-OF-CARE HEPATITIS C TESTING AND TREATING STRATEGY IN PEOPLE WHO INJECT DRUGS IN HARM REDUCTION AND ADDICTION CENTERS FOR HEPATITIS C ELIMINATION - (11/13/20)
 
COST-EFFECTIVENESS OF ANTENATAL RESCREENING AMONG PREGNANT WOMEN FOR HEPATITIS C IN THE UNITED STATES (11/20/20)
 
Global prevalence of hepatitis C virus in women of childbearing age in 2019: a modelling study - HCV Elimination - (02/04/21)
 
Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir - (12/04/20)
 
Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study - (11/24/20)
 
Effectiveness of sofosbuvir/velpatasvir (SOF/VEL) in patients with chronic HCV infection and mental health disorders: real-world care management from 8 countries - (11/13/20)
 
Real-World Outcomes in Patients With Chronic Hepatitis C Virus Infection and Substance Use Disorders Treated With Glecaprevir/Pibrentasvir for 8 Weeks: A Pooled Analysis of Multinational Postmarketing Observational Studies - (11/13/20)
 
Integrated Efficacy and Safety Analysis of Genotypes 1-6 Treatment-Naïve, Non-Cirrhotic, and Compensated Cirrhotic Hispanic/Latino Patients Who Received 8 Weeks of Glecaprevir/Pibrentasvir - (11/13/20)
 
Real-World Outcomes in Patients With Chronic Hepatitis C Virus Infection and Substance Use Disorders Treated With Glecaprevir/Pibrentasvir for 8 Weeks: A Pooled Analysis of Multinational Postmarketing Observational Studies -(11/19/20)
 
The value of sofosbuvir/velpatasvir (SOF/VEL) as a pangenotypic and panfibrotic HCV treatment in implementing a test-and-treat strategy in prisons: real-world care management from 6 countries - (11/13/20)
 
HCV elimination in homeless patients is possible: a pooled real-world analysis of homeless patients with HCV treated with sofosbuvir/velpatasvir (SOF/VEL) for 12 weeks - (11/13/20)
 
Safety, Efficacy, and Pharmacokinetic Analysis of Glecaprevir/Pibrentasvir in Pediatric Patients With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection: Part 2 of the DORA Study - (11/13/20)
 
Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adolescents With Chronic Hepatitis C Virus Infection - (11/16/20)
 
Safety and Efficacy of Sofosbuvir/Velpatasvir for the Treatment of Chronic Hepatitis C Infection in Children and Adolescents Aged 3 to 17 Years Old Through 24 Weeks Posttreatment - (11/16/20)
 
The "Keep It Simple and Safe" Approach to HCV Treatment: Primary Outcomes from the ACTG A5360 (MINMON) Study - (11/19/20)
 
Statins Tied to Lower HCC Risk in HBV Group Without Cirrhosis - (11/17/20)
 
HCC, Decompensation, Alcohol, Tied to Death in Liver Patients With COVID-19 - (11/19/20)

 
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org